[1]王鹏飞,李崇慧.加味沙参麦冬汤联合安罗替尼治疗晚期非小细胞肺癌的临床观察[J].医学信息,2021,34(02):167-170.[doi:10.3969/j.issn.1006-1959.2021.02.047]
　WANG Peng-fei,LI Chong-hui.Clinical Observation of Modified Shashen Maidong Decoction Combined with Anlotinib in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2021,34(02):167-170.[doi:10.3969/j.issn.1006-1959.2021.02.047]
点击复制

加味沙参麦冬汤联合安罗替尼治疗晚期非小细胞肺癌的临床观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年02期
页码:
167-170
栏目:
中医中药
出版日期:
2021-01-15

文章信息/Info

Title:
Clinical Observation of Modified Shashen Maidong Decoction Combined with Anlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
文章编号:
1006-1959（2021）02-0167-04
作者:
王鹏飞; 李崇慧
（1.安徽中医药大学研究生院，安徽 合肥 230012； 2.安徽中医药大学第一附属医院肿瘤二科，安徽 合肥 230031）
Author(s):
WANG Peng-fei; LI Chong-hui
(1.Graduate School,Anhui University of Chinese Medicine,Hefei 230012,Anhui,China; 2.Department of Oncology,the First Affiliated Hospital of Anhui University of Chinese Medicine,Hefei 230031,Anhui,China)
关键词:
非小细胞肺癌; 沙参麦冬汤; 安罗替尼
Keywords:
NSCLC; Shashen Maidong Decoction; Anlotinib
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2021.02.047
文献标志码:
A
摘要:
目的 观察加味沙参麦冬汤联合安罗替尼治疗晚期非小细胞肺癌（NSCLC）的临床疗效。方法 选取2018年6月~2019年6月我院就诊的晚期NSCLC患者40例作为研究对象，随机分为对照组和观察组，每组20例。对照组给予安罗替尼治疗，观察组在对照组的基础上联合加味沙参麦冬汤，比较两组近期疗效、生存质量（KPS）评分、不良反应及生存率（6个月、12个月）。结果 观察组DCR为85.00%，与对照组的80.00%比较，差异无统计学意义（P＞0.05）。观察组KPS评分总有效率高于对照组，差异有统计学意义（P＜0.05）；观察组乏力、厌食发生率低于对照组，差异有统计学意义（P＜0.05）；其他不良反应比较，差异无统计学意义（P＞0.05）；观察组6个月生存率为85.00，高于对照组的55.00%，差异有统计学意义（P＜0.05）；两组12个月生存率比较，差异无统计学意义（P＞0.05）。结论 晚期NSCLC患者采用加味沙参麦冬汤联合安罗替尼治疗，可提高生存率，改善生存质量，缓解靶向治疗毒副反应，提高患者对靶向治疗的耐受性。
Abstract:
Objective To observe the clinical efficacy of Jiawei Shashen Maidong Decoction combined with Anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC).Methods 40 patients with advanced NSCLC who were treated in our hospital from June 2018 to June 2019 were selected as the research objects, and they were randomly divided into a control group and an observation group, with 20 cases in each group. The control group was treated with Anlotinib, and the observation group was combined with Jiawei Shashen Maidong Decoction on the basis of the control group.The short-term efficacy, quality of life (KPS) score, adverse reactions and survival rates (6 months, 12 months) were compared between the two groups.Results The DCR of the observation group was 85.00%, compared with 80.00% of the control group, the difference was not statistically significant (P>0.05).The total effective rate of KPS score in the observation group was higher than that in the control group,the difference was statistically significant (P＜0.05);The incidence of fatigue and anorexia in the observation group was lower than that in the control group,the difference was statistically significant (P＜0.05);Compared with other adverse reactions, the difference was not statistically significant (P>0.05);The 6-month survival rate of the observation group was 85.00%, which was higher than 55.00% of the control group,the difference was statistically significant (P＜0.05);There was no significant difference in the 12-month survival rate between the two groups (P>0.05).Conclusion The treatment of advanced NSCLC patients with Jiawei Shashen Maidong Decoction combined with Anlotinib can improve the survival rate, improve the quality of life, alleviate the side effects of targeted therapy, and improve the patient’s tolerance to targeted therapy.

参考文献/References:

[1]王宁,刘硕,杨雷,等.2018全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2019,5(1):87-97. [2]Gettinger S,Horn L,Jackman D,et al.Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer:Results From the CA209-003 Study[J].Journal of Clinical Oncology,2018,36(17):1675-1684. [3]刘丽娅,朱颖,涂长玲,等.小分子抗血管生成药物在非小细胞肺癌中的研究进展[J].现代肿瘤医学,2020,28(4):663-667. [4]韩宝惠,李凯,周彩存,等.晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2019版)[J].中国肺癌杂志,2019,22(7):401-412. [5]徐升,徐经世.国医大师徐经世治疗肺癌学术经验[J].山东中医杂志,2018,37(4):319-321. [6]张艳.EGFR-TKI联合化疗一线治疗EGFR突变阳性NSCLC的随机对照研究[D].山东大学,2017. [7]霍飞,张蕊.1996-2015年吸烟与肺癌国际研究状况文献计量学分析[J].中国慢性病预防与控制,2016,24(6):477-478. [8]陈文杰,李高峰.非小细胞肺癌的分子靶向治疗研究进展[J]. 现代肿瘤医学,2017,25(12):1994-1996. [9]李蓉,谭小武.安罗替尼治疗晚期非小细胞肺癌的疗效及安全性评估[J].现代医药卫生,2019,35(18):2815-2817. [10]冯久桓,秦叔逵,王琳.甲磺酸阿帕替尼的研究现状与进展[J].临床肿瘤学杂志,2017,22（4）：345-356. [11]王睿晴,张艳华.抗肿瘤分子靶向药物安罗替尼的临床研究进展[J].中国新药杂志,2018,27(23):2770-2774. [12]沈娟,陈雪琴,马胜林.安罗替尼抗肿瘤作用研究进展[J].浙江医学,2019,41(23):2556-2560. [13]王俊,冉凤鸣,金兵.安罗替尼治疗恶性肿瘤的临床研究进展[J].中国肿瘤,2019,28(5):359-366. [14]Baohui H,Kai L,Yizhuo Z,et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer:a multicentre,randomised phase II trial(ALTER0302)[J].British Journal of Cancer,2018,118(5):654-661. [15]Han B,Li K,Wang Q,et al.Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer:The ALTER 0303 Phase 3 Randomized Clinical Trial[J].JAMA Oncology,2018,4(11):1569-1575. [16]韩骐蔓,侯和磊,张晓春.国产创新药安罗替尼抗肿瘤治疗的研究进展[J].中国新药与临床杂志,2020,39(2):65-70. [17]李崇慧.徐经世老中医治疗恶性消化道肿瘤经验[J].中国中医急症,2008(6):800-832. [18]杨忠光,梁鑫,赵远桥.沙参麦冬汤联合化疗对气阴两虚型肺癌患者免疫功能及炎性反应的影响[J].中国实验方剂学杂志,2017,23(16):158-163. [19]李海舟.沙参麦冬汤对中晚期非小细胞肺癌患者免疫功能及生活质量的影响[J].吉林医药学院学报,2019,40(3):197-198.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,31(02):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,31(02):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,31(02):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,31(02):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,32(02):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,31(02):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,31(02):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(02):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2022,35(02):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Medical Information,2019,32(02):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 1900-01-01